KRAS and non-small cell lung carcinoma: Recently, two small molecules KRAS inhibitors, sotorasib and adagrasib were granted FDA approval in 2021 and in 2022 for the treatment of KRAS G12C mutant non-small cell lung cancer (Rathod et al., 2023).